AzTrials
AzTrials

HIV InfectionNCT00247091

Impact of HIV on Measles and Measles Immunisation

An observational study of HIV Infection and Measles, run by Johns Hopkins Bloomberg School of Public Health at 1 site in Zambia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

We conducted a longitudinal study to assess the immunogenicity of standard-titer measles vaccine in HIV-infected and uninfected Zambian children. The study hypothesis was that HIV-infected children would have higher rates of primary and secondary measles vaccine failure compared to uninfected children, contributing to… Read more about this study

Who is it for?
Ages 2 to 15 monthsHealthy volunteers can take part
Conditions the study is for
HIV Infection, Measles, Children
What is being tested?
standard-titer measles vaccine
Type of treatment
Vaccines
How many people
700 participants
Where
1 siteZambia
Study dates
May 2000to Sep 2004
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 15 months
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • children aged 2 to 8 months presenting for well-child care
  • reside within 10 miles of the study clinic
  • parents or caretakers provide signed informed consent

Who cannot join

  • -children with severe illness

Trial locations and contacts

1 site in 1 country.

Zambia1 site
  • Chawama Clinic

    Lusaka

Other trials in Zambia

About this study

We conducted a longitudinal study to assess the immunogenicity of standard-titer measles vaccine in HIV-infected and uninfected Zambian children. The study hypothesis was that HIV-infected children would have higher rates of primary and secondary measles vaccine failure compared to uninfected children, contributing to decreased levels of population immunity to measles and facilitating measles virus transmission in regions of high HIV prevalence.

Read the detailed description

Despite great progress in measles control in sub-Saharan Africa, measles remains a significant cause of morbidity and mortality in young children. In regions of high HIV prevalence, measles virus transmission may be sustained despite high immunization coverage rates if HIV-infected children are important transmitters of measles virus. Factors potentially contributing to enhanced measles virus transmission by HIV-infected children include an early decline in protective maternal antibody titers resulting in susceptibility to measles at a younger age, and high rates of primary and secondary measles vaccine failure. To evaluate the potential impact of the HIV-1 epidemic on immunity following measles vaccination, we conducted a longitudinal study to compare the primary vaccine failure rate and rate of antibody decline following administration of standard-titer measles vaccine at nine months of age to HIV-infected and HIV-uninfected Zambian children. Our results show that children born to HIV-infected women have lower levels of passively-acquired maternal antibodies to measles virus prior to the age of routine vaccination at 9 months, and HIV-infected children are particularly susceptible to measles in infancy. This finding supports the WHO recommendation to provide the first dose of measles vaccine to HIV-infected children at 6 months. Furthermore, HIV-infected children develop adequate primary antibody responses to measles vaccine in the months following vaccination but lose protective antibody titers by two to three years of age. Mitigating the potential impact of this decreased immunogenicity on the level of population immunity to measles virus was the high mortality rate observed among HIV-infected children. Improved access to antiretroviral therapy will likely improve the survival of HIV-infected children without enhancing protective immunity to measles virus, although this has yet to be investigated. We are working to incorporate our findings into a mathematical model to better understand the impact of the HIV-1 epidemic on measles control strategies and to investigate the immunologic mechanisms for impaired memory B cell responses in HIV-infected children.

Being tested
standard-titer measles vaccine
Keywords
HIV, measles, measles vaccine, children, Zambia
Medical subject headings
HIV Infections, Measles

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • standard-titer measles vaccineBiological

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2005 (estimated)
  2. Study startMay 2000
  3. Study completionSep 2004

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Defined population
Time perspective
Prospective
Enrolment
700 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00247091
Sponsor's protocol ID
GR059114MA
Status last verified
Oct 2005
First submitted
28 Oct 2005
Last updated
1 Nov 2005
Results posted
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in